Search

Your search keyword '"Sevin E"' showing total 234 results
Start Over Author "Sevin E"
234 results on '"Sevin E"'

6. 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

Author

Oudard, S., primary, Beuzeboc, P., additional, Voog, E., additional, Barthelemy, P., additional, Thiery-Vuillemin, A., additional, Bennamoun, M., additional, Hasbini, A., additional, Aldabbagh, K., additional, Saldana, C., additional, Sevin, E., additional, Amela, Y.E., additional, Von Amsberg, G., additional, Houede, N., additional, Besson, D., additional, Feyerabend, S., additional, Boegemann, M., additional, Pfister, D., additional, Schostak, M., additional, Huillard, O., additional, and Helissey, C., additional

Published
2022
Full Text
View/download PDF

10. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Author

du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo JM, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, Mr, Scambia, G, Meier, W, Nicoletto, Mo, Bjørge, L, Lortholary, A, Sailer, Mo, Merger, M, Harter, P, AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium: Università degli Studi di Torino ITA, Ferrero, A, Et, Al, du Bois, A, Kristensen, G, Ray Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo, J, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, M, Scambia, G, Meier, W, Nicoletto, M, Bjørge, L, Lortholary, A, Sailer, M, Merger, M, and Harter, P

Subjects
0301 basic medicine, Indoles, Clinical Trial, Phase III, Medizin, ovarian cancer nintedanib angiogenesis inhibitor chemotherapy ENGOT clinical trial, Gastroenterology, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine, Peritoneal Neoplasms, Aged, 80 and over, Ovarian Neoplasms, education.field_of_study, Medicine (all), Research Support, Non-U.S. Gov't, Anemia, Cytoreduction Surgical Procedures, Middle Aged, Intention to Treat Analysis, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Multicenter Study, Oncology, Tolerability, 030220 oncology & carcinogenesis, Randomized Controlled Trial, Disease Progression, Female, Nintedanib, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Neutropenia, Paclitaxel, Bevacizumab, Population, Placebo, Disease-Free Survival, Young Adult, 03 medical and health sciences, Double-Blind Method, Internal medicine, Journal Article, Fallopian Tube Neoplasms, Humans, Progression-free survival, education, Response Evaluation Criteria in Solid Tumors, Aged, Neoplasm Staging, business.industry, Carcinoma, medicine.disease, Thrombocytopenia, Surgery, Settore MED/40 - GINECOLOGIA E OSTETRICIA, 030104 developmental biology, chemistry, business, Febrile neutropenia
Abstract

BACKGROUND: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer.METHODS: In this double-blind phase 3 trial, chemotherapy-naive patients (aged 18 years or older) with International Federation of Gynecology and Obstetrics (FIGO) IIB-IV ovarian cancer and upfront debulking surgery were stratified by postoperative resection status, FIGO stage, and planned carboplatin dose. Patients were randomly assigned (2:1) via an interactive voice or web-based response system to receive six cycles of carboplatin (AUC 5 mg/mL per min or 6 mg/mL per min) and paclitaxel (175 mg/m(2)) in addition to either 200 mg of nintedanib (nintedanib group) or placebo (placebo group) twice daily on days 2-21 of every 3-week cycle for up to 120 weeks. Patients, investigators, and independent radiological reviewers were masked to treatment allocation. The primary endpoint was investigator-assessed progression-free survival analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01015118.FINDINGS: Between Dec 9, 2009, and July 27, 2011, 1503 patients were screened and 1366 randomly assigned by nine study groups in 22 countries: 911 to the nintedanib group and 455 to the placebo group. 486 (53%) of 911 patients in the nintedanib group experienced disease progression or death compared with 266 (58%) of 455 in the placebo group. Median progression-free survival was significantly longer in the nintedanib group than in the placebo group (17·2 months [95% CI 16·6-19·9] vs 16·6 months [13·9-19·1]; hazard ratio 0·84 [95% CI 0·72-0·98]; p=0·024). The most common adverse events were gastrointestinal (diarrhoea: nintedanib group 191 [21%] of 902 grade 3 and three [INTERPRETATION: Nintedanib in combination with carboplatin and paclitaxel is an active first-line treatment that significantly increases progression-free survival for women with advanced ovarian cancer, but is associated with more gastrointestinal adverse events. Future studies should focus on improving patient selection and optimisation of tolerability.FUNDING: Boehringer Ingelheim.

Published
2016
Full Text
View/download PDF

18. «Nano-réacteurs à base de cyclodextrines amphiphiles pour la catalyse et la vectorisation»

Author

Oliva, E., Mathiron, D., Bonnet, V., Pilard, S., Cocq, A., Bricout, H., Tilloy, S., Léger, B., Monflier, E., Sevin, E., Fenart, L., Gosselet, F., Djedaïni-Pilard, F., Université de Picardie Jules Verne (UPJV), Unité de Catalyse et Chimie du Solide - UMR 8181 (UCCS), Centrale Lille Institut (CLIL)-Université d'Artois (UA)-Centrale Lille-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Lille, Laboratoire des Glucides (LG), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Picardie Jules Verne (UPJV), UCCS Équipe Catalyse Supramoléculaire, Centrale Lille Institut (CLIL)-Université d'Artois (UA)-Centrale Lille-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Lille-Centrale Lille Institut (CLIL)-Université d'Artois (UA)-Centrale Lille-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Lille, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université d'Artois (UA), Université d'Artois (UA)-Centrale Lille-Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Université de Picardie Jules Verne (UPJV)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), and Université d'Artois (UA)-Centrale Lille-Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université d'Artois (UA)-Centrale Lille-Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)

Subjects
[CHIM]Chemical Sciences, ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2017

19. Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial

Author

Oudard, S., primary, Latorzeff, I., additional, Caty, A., additional, Miglianico, L., additional, Sevin, E., additional, Hardy Bessard, A-C., additional, Delva, R., additional, Rolland, F., additional, Chevreau, C., additional, Priou, F., additional, Beuzeboc, P., additional, Gravis, G., additional, Linassier, C., additional, Gomez, P., additional, Voog, E., additional, Chinet, P., additional, Muracciole, X., additional, Abraham Jaillon, C., additional, Elaidi, R., additional, and Culine, S., additional

Published
2017
Full Text
View/download PDF

21. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Bois, A. du, Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Campo, J.M. Del, Ottevanger, P.B., Heubner, M., Minarik, T., Sevin, E., Gregorio, N. de, Bidzinski, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M.R., Scambia, G., Meier, W., Nicoletto, M.O., Bjorge, L., Lortholary, A., Sailer, M.O., Merger, M., Harter, P., Bois, A. du, Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Campo, J.M. Del, Ottevanger, P.B., Heubner, M., Minarik, T., Sevin, E., Gregorio, N. de, Bidzinski, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M.R., Scambia, G., Meier, W., Nicoletto, M.O., Bjorge, L., Lortholary, A., Sailer, M.O., Merger, M., and Harter, P.

Abstract

Item does not contain fulltext, BACKGROUND: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer. METHODS: In this double-blind phase 3 trial, chemotherapy-naive patients (aged 18 years or older) with International Federation of Gynecology and Obstetrics (FIGO) IIB-IV ovarian cancer and upfront debulking surgery were stratified by postoperative resection status, FIGO stage, and planned carboplatin dose. Patients were randomly assigned (2:1) via an interactive voice or web-based response system to receive six cycles of carboplatin (AUC 5 mg/mL per min or 6 mg/mL per min) and paclitaxel (175 mg/m(2)) in addition to either 200 mg of nintedanib (nintedanib group) or placebo (placebo group) twice daily on days 2-21 of every 3-week cycle for up to 120 weeks. Patients, investigators, and independent radiological reviewers were masked to treatment allocation. The primary endpoint was investigator-assessed progression-free survival analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01015118. FINDINGS: Between Dec 9, 2009, and July 27, 2011, 1503 patients were screened and 1366 randomly assigned by nine study groups in 22 countries: 911 to the nintedanib group and 455 to the placebo group. 486 (53%) of 911 patients in the nintedanib group experienced disease progression or death compared with 266 (58%) of 455 in the placebo group. Median progression-free survival was significantly longer in the nintedanib group than in the placebo group (17.2 months [95% CI 16.6-19.9] vs 16.6 months [13.9-19.1]; hazard ratio 0.84 [95% CI 0.72-0.98]; p=0.024). The most common adverse events were gastrointestina

Published
2016

22. 433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC)

Author

Oudard, S., primary, Benhamouda, N., additional, Escudier, B., additional, Ravel, P., additional, Kothari, D., additional, Mehmud, F., additional, Levionnois, E., additional, Sevin, E., additional, Negrier, S., additional, Barthelemy, P., additional, Berdah, J.F., additional, Ravaud, A., additional, Sternberg, C.N., additional, Bono, P., additional, Porta, C., additional, Giorgi, U. De, additional, Parikh, O., additional, Hawkins, R., additional, Highley, M., additional, Tartour, E., additional, Decker, T., additional, and Wilkie, J., additional

Published
2015
Full Text
View/download PDF

23. La pratique du camping : en quête de vie sociale idéalisée

Author

Ladwein, R., Sevin, E., Legrand, Annette, A. Decrop, UMR CNRS 8179, and Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SHS.GESTION]Humanities and Social Sciences/Business administration, [SHS.GESTION] Humanities and Social Sciences/Business administration
Published
2010

25. Demo: Have a Chat with Sensitive Artificial Listeners

Author

Schröder, M., Pammi, S., Cowie, R., McKeown, G., Gunes, H., Pantic, M., Valstar, M., Heylen, D., ter Maat, M., Eyben, F., Schuller, B., Wöllmer, M., Bevacqua, E., C., Pelachaud, Etienne de Sevin, E., and Lehrstuhl für Mensch-Maschine-Kommunikation

Subjects
ddc
Published
2009

27. 784O - Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial

Author

Oudard, S., Latorzeff, I., Caty, A., Miglianico, L., Sevin, E., Hardy Bessard, A-C., Delva, R., Rolland, F., Chevreau, C., Priou, F., Beuzeboc, P., Gravis, G., Linassier, C., Gomez, P., Voog, E., Chinet, P., Muracciole, X., Abraham Jaillon, C., Elaidi, R., and Culine, S.

Published
2017
Full Text
View/download PDF

30. Is There a Relationship Between Patient'S Satisfaction of the Diagnosis Announcement Device and Chemotherapy-Induced Nausea and Vomiting?

Author

Gouerant, S., primary, Dugue, A.E., additional, Vanboeckstael, J., additional, Allouache, D., additional, Noal, S., additional, Faveyrial, A., additional, Delcambre, C., additional, Galais, M., additional, Lefebvre, A., additional, Sevin, E., additional, Polycarpe, F., additional, Hrab, I., additional, Brachet, P.E., additional, Kaluzinski, L., additional, Ngo, M.D., additional, Vie, B., additional, Lemenand, N., additional, Grellard, J., additional, Clarisse, B., additional, and Joly Lobbedez, F., additional

Published
2014
Full Text
View/download PDF

31. Is docetaxel-prednisone (DP) feasible in frail elderly (75+) patient with castration-resistant metastatic prostate cancer (CRMPC)? A prospective randomized study after geriatric assessment from gerico and getug unicancer groups

Author

Mourey, L., primary, Gravis-Mescam, G., additional, Sevin, E., additional, Priou, F., additional, Bompas, E., additional, Sarda, C., additional, Houede, N., additional, Carola, E., additional, Abadie, S., additional, Latorzeff, I., additional, Orsini, C., additional, and Filleron, T., additional

Published
2013
Full Text
View/download PDF

34. Building Autonomous Sensitive Artificial Listeners

Author

Schroder, M., primary, Bevacqua, E., additional, Cowie, R., additional, Eyben, F., additional, Gunes, H., additional, Heylen, D., additional, ter Maat, M., additional, McKeown, G., additional, Pammi, S., additional, Pantic, M., additional, Pelachaud, C., additional, Schuller, B., additional, de Sevin, E., additional, Valstar, M., additional, and Wollmer, M., additional

Published
2012
Full Text
View/download PDF

37. Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survival

Author

Oudard, S., primary, Latorzeff, I., additional, Beuzeboc, P., additional, Banu, E., additional, Caty, A., additional, Sevin, E., additional, Delva, R., additional, Rolland, F., additional, Priou, F., additional, Elaidi, R., additional, and Culine, S., additional

Published
2011
Full Text
View/download PDF

39. Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy ± docetaxel—An analysis of final safety results.

Author

Oudard, S., primary, Latorzeff, I., additional, Beuzeboc, P., additional, Caty, A., additional, Sevin, E., additional, Delva, R., additional, Rolland, F., additional, Mourey, L., additional, Priou, F., additional, and Culine, S., additional

Published
2010
Full Text
View/download PDF

41. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)

Author

Ravaud, A., primary, Oudard, S., additional, Gravis-Mescam, G., additional, Sevin, E., additional, Zanetta, S., additional, Théodore, C., additional, de Fromont, M., additional, Mahier-Aït Oukhatar, C., additional, Chêne, G., additional, and Escudier, B., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results